How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
Don’t Let Failure to Communicate Get in the Way of Effective Technology Transfer in API Manufacturin...
5 important things to look for in your CMO's Project management Capabilities
Three Ways to Save Money when Managing Impurities During API Scale-Up
Cryogenics: How Cryogenic Capabilities Aid API Development
PCI Synthesis at DCAT Week 2017
About the Author
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...